Calvisi et al. later showed that B-Myb is progressively up-regulated during HCC development and progression, and that the highest expression levels of B-Myb are associated with poorer outcomes in HCC patients [10]. This evidence concerns the gene MYBL2 and hepatocellular carcinoma.